<DOC>
	<DOCNO>NCT01229566</DOCNO>
	<brief_summary>The primary objective determine efficacy AKR963 compare placebo active comparator lower fast triglyceride level patient high fast triglyceride level ≥ 500 ≤ 1500 mg/dL .</brief_summary>
	<brief_title>Efficacy Study Treat Subjects With Severe Hypertriglyceridemia</brief_title>
	<detailed_description>Increases triglyceride concentration correlate increase risk pancreatitis well coronary heart disease ( Ginsberg 2001 , 2002 ) . The incidence rate major coronary event Munster Heart Study increase 4.4 % among Subjects baseline TG concentration 200 mg/dL 9.3 % among Subjects TG concentration 200-399 mg/dL range , 13.2 % Subjects TG level range 400-799 mg/dL ( Assmann 1996 ) .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Men woman , age 1879 Fasting triglyceride ≥500 mg/dL ≤1500 mg/dL Provide write informed consent authorization protect health information disclosure Women pregnant lactating , plan become pregnant Use nonstatin lipidaltering drug stop supplement potential lipidaltering effect History pancreatitis History bariatric surgery currently weight loss drug weight loss program Treatment agent may affect lipid level hepatic function Consumption 3 alcoholic beverage per day History cancer within last 2 year Participation another clinical trial involve investigational agent last 30 day Other parameter assess study center ensure eligibility study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>